Opaleye Management Inc.

Opaleye Management Inc. reported 58 holdings worth US$888M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Opaleye Management Inc. reported 58 holdings worth US$888M as of Sep 30, 2026. Largest: Eton Pharmaceuticals, Inc., Disc Medicine, Inc. and Harrow, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
58
Value as reported
US$888M

The filing in full

CompanySharesValue as reported% of portfolio
Eton Pharmaceuticals, Inc.2.44MUS$126M14.2%
Disc Medicine, Inc.1.09MUS$71.7M8.1%
Harrow, Inc.2.1MUS$64.8M7.3%
Liquidia Corporation2.11MUS$63.8M7.2%
MeiraGTx Holdings plc3.6MUS$39.6M4.5%
TG Therapeutics, Inc.557KUS$31.1M3.5%
Alpha Cognition Inc.3.3MUS$29.7M3.3%
Immix Biopharma, Inc.2.83MUS$29.4M3.3%
Crescent Biopharma, Inc.1.65MUS$24M2.7%
Verastem, Inc.2.75MUS$22.2M2.5%
Revolution Medicines, Inc.100KUS$20.5M2.3%
Replimune Group, Inc.1.38MUS$18.3M2.1%
Stoke Therapeutics, Inc.692KUS$18M2.0%
Summit Therapeutics Inc.1.05MUS$17.8M2.0%
Rezolute, Inc.4.09MUS$16.9M1.9%
Biohaven Ltd.1.19MUS$15.9M1.8%
Protagonist Therapeutics, Inc.100KUS$14.1M1.6%
Monte Rosa Therapeutics, Inc.1.03MUS$12.3M1.4%
Rhythm Pharmaceuticals, Inc.123KUS$11.7M1.3%
Q32 Bio Inc.1.12MUS$9.26M1.0%
Harmony Biosciences Holdings, Inc.230KUS$9.03M1.0%
Editas Medicine, Inc.3.49MUS$8.96M1.0%
Alumis Inc.1MUS$7.4M0.83%
Edgewise Therapeutics, Inc.175KUS$7.11M0.80%
Grace Therapeutics, Inc.2.8MUS$6.02M0.68%
Syndax Pharmaceuticals, Inc.315KUS$5.93M0.67%
Jasper Therapeutics, Inc.281KUS$4.89M0.55%
4D Molecular Therapeutics, Inc.334KUS$4.79M0.54%
Inhibrx Biosciences, Inc.45,500US$4.55M0.51%
Cabaletta Bio, Inc.2.32MUS$4.46M0.50%
Trevi Therapeutics, Inc.310KUS$4.44M0.50%
Voyager Therapeutics, Inc.1.63MUS$4.37M0.49%
Zentalis Pharmaceuticals, Inc.1.41MUS$3.91M0.44%
Ocular Therapeutix, Inc.506KUS$3.88M0.44%
Relmada Therapeutics, Inc.1MUS$3.77M0.42%
Annexon, Inc.875KUS$3.7M0.42%
Opus Genetics, Inc.750KUS$3.63M0.41%
Codexis, Inc.2.59MUS$3.6M0.41%
BlossomHill Therapeutics, Inc.175KUS$3.26M0.37%
Lyell Immunopharma, Inc.291KUS$2.85M0.32%
Rocket Pharmaceuticals, Inc.1MUS$2.63M0.30%
Biodesix, Inc.87,000US$2.6M0.29%
BridgeBio Oncology Therapeutics, Inc.630KUS$2.58M0.29%
Jade Biosciences, Inc.140KUS$1.97M0.22%
Enanta Pharmaceuticals, Inc.125KUS$1.65M0.19%
Fortress Biotech, Inc.720KUS$1.54M0.17%
SANUWAVE Health, Inc.306KUS$1.44M0.16%
MBX Biosciences, Inc.20,000US$1.17M0.13%
Obsidian Therapeutics, Inc.75,755US$1.04M0.12%
Journey Medical Corporation125KUS$855K0.10%
Korro Bio, Inc.69,348US$687K0.08%
Sionna Therapeutics, Inc.70,000US$368K0.04%
Adagio Medical Holdings, Inc18,444US$2,822<0.01%
XOMA Royalty Corporation0US$00.00%
Apogee Therapeutics, Inc.0US$00.00%
Atea Pharmaceuticals, Inc.0US$00.00%
CG Oncology, Inc.0US$00.00%
First Tracks Biotherapeutics, Inc.0US$00.00%
Hemab Therapeutics Holdings, Inc.0US$00.00%
Intellia Therapeutics, Inc.0US$00.00%
Palatin Technologies, Inc.0US$00.00%
Pasithea Therapeutics Corp.0US$00.00%
Phathom Pharmaceuticals, Inc.0US$00.00%

Source

Download original · View original at SEC

Related